Shares in California-based biotechnology company Erasca (NASDAQ: ERAS) plunged by more than 35% in early US trading on Friday, after the firm announced that its experimental drug for advanced melanoma had failed to meet its primary efficacy targets in a mid-stage clinical trial. The company said it would discontinue further development of the candidate, sending the stock to its lowest level in over a year.
Market reaction was swift: the Nasdaq Biotechnology Index fell 0.4% in sympathy, while the broader S&P 500 edged down 0.1% as investors rotated away from high-risk biotech names. London-listed biotech peers saw limited spillover, with the FTSE 100 closing flat at 8,224 points and the FTSE 250 rising 0.2% as UK-focused healthcare stocks such as AstraZeneca and GSK held steady.
Analysts at Jefferies described the trial failure as “a significant blow” to Erasca’s pipeline, which was heavily reliant on the melanoma drug. The company now faces a strategic reset, with cash reserves sufficient to fund operations into mid-2027, according to its latest quarterly filing. For UK investors holding US-focused biotech exchange-traded funds (ETFs), the impact is likely to be modest, given Erasca’s relatively small market capitalisation of roughly £1.2bn before the sell-off.
The broader context for UK pension holders is that UK equity portfolios typically have low single-digit exposure to US small-cap biotech. However, those with actively managed global growth funds or thematic healthcare ETFs may see marginal volatility. “This is a company-specific event, not a sector-wide signal,” said Dr Helen Marsh, healthcare analyst at Panmure Liberum. “UK investors should view it as a reminder of the binary risk inherent in early-stage drug development.”
Erasca’s setback also highlights the challenges facing the melanoma treatment landscape, where established immunotherapies from Merck and Bristol Myers Squibb dominate. The company has not indicated any plans for a strategic sale or partnership, and its remaining pipeline includes early-stage programmes for other cancers, none of which are expected to enter late-stage trials before 2027.